Advertisement

Ketamine pp 105-125 | Cite as

Antidepressant Actions of Ketamine and Its Two Enantiomers

  • Lijia Chang
  • Yan Wei
  • Kenji HashimotoEmail author
Chapter
  • 46 Downloads

Abstract

The N-methyl-d-aspartate receptor antagonist ketamine has been widely used as an off-label medication to treat depression because it elicits rapid and robust antidepressant effects in treatment-resistant patients with depression. (R,S)-ketamine is a racemic mixture containing equal amounts of (R)-ketamine (or arketamine) and (S)-ketamine (or esketamine). On March 5, 2019, the United States Food and Drug Administration approved an (S)-ketamine nasal spray for treatment-resistant depression. In contrast, (R)-ketamine has been reported to have a greater potency and longer-lasting antidepressant effects than (S)-ketamine in rodent models of depression. However, the precise mechanisms underlying the robust antidepressant effects of ketamine enantiomers remain unknown. In this chapter, we discuss recent findings on the antidepressant actions of two enantiomers of ketamine.

Keywords

Arketamine Ketamine Esketamine 

Notes

Acknowledgments

This study was supported by grant from AMED, Japan (to K.H., JP19dm0107119). Dr. Lijia Chang was supported by the Japan China Sasakawa Medical Fellowship (Tokyo, Japan). Dr. Yan Wei (Southwest Medical University, China) was supported by the China Scholarship Council (China).

Disclosure Statement: Dr. Hashimoto is the inventor of filed patent applications on “The use of R-ketamine in the treatment of psychiatric diseases” by the Chiba University. Dr. Hashimoto also declares that he has received research support and consultant from Dainippon Sumitomo, Otsuka, and Taisho.

References

  1. Abdallah CG et al (2019) Repeated ketamine infusions for antidepressant-resistant PTSD: methods of a multicenter, randomized, placebo-controlled clinical trial. Contemp Clin Trials 81:11–18.  https://doi.org/10.1016/j.cct.2019.04.009CrossRefPubMedGoogle Scholar
  2. Ajub E, Lacerda ALT (2018) Efficacy of esketamine in the treatment of depression with psychotic features: a case series. Biol Psychiatry 83:e15–e16.  https://doi.org/10.1016/j.biopsych.2017.06.011CrossRefPubMedGoogle Scholar
  3. Al Shirawi MI, Kennedy SH, Ho KT, Byrne R, Downar J (2017) Oral ketamine in treatment-resistant depression: a clinical effectiveness case series. J Clin Psychopharmacol 37:464–467.  https://doi.org/10.1097/JCP.0000000000000717CrossRefPubMedPubMedCentralGoogle Scholar
  4. Andrade C (2017) Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry 78:e852–e857.  https://doi.org/10.4088/JCP.17f11738CrossRefPubMedGoogle Scholar
  5. Andrade C (2019) Oral ketamine for depression, 2: practical considerations. J Clin Psychiatry 80.  https://doi.org/10.4088/JCP.19f12838
  6. Ardalan M, Rafati AH, Nyengaard JR, Wegener G (2017) Rapid antidepressant effect of ketamine correlates with astroglial plasticity in the hippocampus. Br J Pharmacol 174:483–492.  https://doi.org/10.1111/bph.13714CrossRefPubMedPubMedCentralGoogle Scholar
  7. Bartoli F, Riboldi I, Crocamo C, Di Brita C, Clerici M, Carra G (2017) Ketamine as a rapid-acting agent for suicidal ideation: a meta-analysis. Neurosci Biobehav Rev 77:232–236.  https://doi.org/10.1016/j.neubiorev.2017.03.010CrossRefPubMedPubMedCentralGoogle Scholar
  8. Bartova L, Vogl SE, Stamenkovic M, Praschak-Rieder N, Naderi-Heiden A, Kasper S, Willeit M (2015) Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: a report of two cases. Eur Neuropsychopharmacol 25:2183–2184.  https://doi.org/10.1016/j.euroneuro.2015.07.021CrossRefPubMedGoogle Scholar
  9. Becker A, Peters B, Schroeder H, Mann T, Huether G, Grecksch G (2003) Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:687–700.  https://doi.org/10.1016/S0278-5846(03)00080-0CrossRefGoogle Scholar
  10. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354CrossRefGoogle Scholar
  11. Bobo WV, Vande Voort JL, Croarkin PE, Leung JG, Tye SJ, Frye MA (2016) Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice. Depress Anxiety 33:698–710.  https://doi.org/10.1002/da.22505CrossRefPubMedGoogle Scholar
  12. Calvey TN (1995) Isomerism and anaesthetic drugs. Acta Anaesthesiol Scand Suppl 106:83–90CrossRefGoogle Scholar
  13. Canady VA (2019) Nasal spray treatment for adults with TRD approved by FDA. Mental Health Wkly 29:4–5Google Scholar
  14. Chan KW, Lee TM, Siu AM, Wong DP, Kam CM, Tsang SK, Chan CC (2013) Effects of chronic ketamine use on frontal and medial temporal cognition. Addict Behav 38:2128–2132.  https://doi.org/10.1016/j.addbeh.2013.01.014CrossRefPubMedPubMedCentralGoogle Scholar
  15. Chang L et al (2019a) Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacol Biochem Behav 181:53–59.  https://doi.org/10.1016/j.pbb.2019.04.008CrossRefPubMedGoogle Scholar
  16. Chang L et al (2019b) Lack of dopamine D1 receptors in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model. Eur Arch Psychiatry Clin Neurosci.  https://doi.org/10.1007/s00406-019-01012-1CrossRefGoogle Scholar
  17. Chaturvedi HK, Chandra D, Bapna JS (1999) Interaction between N-methyl-D-aspartate receptor antagonists and imipramine in shock-induced depression. Indian J Exp Biol 37:952–958PubMedGoogle Scholar
  18. Cohen SP et al (2018) Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med 43:521–546.  https://doi.org/10.1097/AAP.0000000000000808CrossRefPubMedPubMedCentralGoogle Scholar
  19. Correia-Melo FS, Silva SS, Araujo-de-Freitas L, Quarantini LC (2017) S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression. Braz J Psychiatry 39:188–189.  https://doi.org/10.1590/1516-4446-2016-2070CrossRefPubMedGoogle Scholar
  20. Correia-Melo FS et al (2018) Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial. Medicine (Baltimore) 97:e12414.  https://doi.org/10.1097/MD.0000000000012414CrossRefGoogle Scholar
  21. Coyle CM, Laws KR (2015) The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol 30:152–163.  https://doi.org/10.1002/hup.2475CrossRefPubMedGoogle Scholar
  22. Cui Y et al (2018) Astroglial Kir4.1 in the lateral habenula drives neuronal bursts in depression. Nature 554:323–327.  https://doi.org/10.1038/nature25752CrossRefPubMedPubMedCentralGoogle Scholar
  23. Cusin C (2019) Ketamine as a rapid antidepressant. In: The Massachusetts General Hospital guide to depression. Springer, Berlin, pp 139–145CrossRefGoogle Scholar
  24. Domino EF (2010) Taming the ketamine tiger. 1965. Anesthesiology 113:678–684.  https://doi.org/10.1097/ALN.0b013e3181ed09a2CrossRefGoogle Scholar
  25. Donahue RJ, Muschamp JW, Russo SJ, Nestler EJ, Carlezon WA Jr (2014) Effects of striatal DeltaFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol Psychiatry 76:550–558.  https://doi.org/10.1016/j.biopsych.2013.12.014CrossRefPubMedPubMedCentralGoogle Scholar
  26. du Jardin KG, Liebenberg N, Muller HK, Elfving B, Sanchez C, Wegener G (2016) Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression. Psychopharmacology (Berl) 233:2813–2825.  https://doi.org/10.1007/s00213-016-4327-5CrossRefGoogle Scholar
  27. du Jardin KG, Liebenberg N, Cajina M, Muller HK, Elfving B, Sanchez C, Wegener G (2017) S-ketamine mediates its acute and sustained antidepressant-like activity through a 5-HT1B receptor dependent mechanism in a genetic rat model of depression. Front Pharmacol 8:978.  https://doi.org/10.3389/fphar.2017.00978CrossRefPubMedGoogle Scholar
  28. Duman RS (2018) Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Res 7.  https://doi.org/10.12688/f1000research.14344.1CrossRefGoogle Scholar
  29. Esketamine (2006) Drugs and lactation database (LactMed). National Library of Medicine (US), Bethesda, MDGoogle Scholar
  30. Fernando AB, Robbins TW (2011) Animal models of neuropsychiatric disorders. Annu Rev Clin Psychol 7:39–61.  https://doi.org/10.1146/annurev-clinpsy-032210-104454CrossRefPubMedGoogle Scholar
  31. Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi JI, Hashimoto K, Chaki S (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther 361:9–16.  https://doi.org/10.1124/jpet.116.239228CrossRefPubMedPubMedCentralGoogle Scholar
  32. Gao M, Rejaei D, Liu H (2016) Ketamine use in current clinical practice. Acta Pharmacol Sin 37:865–872.  https://doi.org/10.1038/aps.2016.5CrossRefPubMedPubMedCentralGoogle Scholar
  33. Giorgetti R, Marcotulli D, Tagliabracci A, Schifano F (2015) Effects of ketamine on psychomotor, sensory and cognitive functions relevant for driving ability. Forensic Sci Int 252:127–142.  https://doi.org/10.1016/j.forsciint.2015.04.024CrossRefPubMedGoogle Scholar
  34. Gowda MR, Srinivasa P, Kumbar PS, Ramalingaiah VH, Muthyalappa C, Durgoji S (2016) Rapid resolution of grief with IV infusion of ketamine: a unique phenomenological experience. Indian J Psychol Med 38:62–64.  https://doi.org/10.4103/0253-7176.175121CrossRefPubMedPubMedCentralGoogle Scholar
  35. Grunebaum MF et al (2018) Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry 175:327–335.  https://doi.org/10.1176/appi.ajp.2017.17060647CrossRefPubMedPubMedCentralGoogle Scholar
  36. Hashimoto K (2016a) Detrimental side effects of repeated ketamine infusions in the brain. Am J Psychiatry 173:1044–1045.  https://doi.org/10.1176/appi.ajp.2016.16040411CrossRefPubMedGoogle Scholar
  37. Hashimoto K (2016b) Ketamine’s antidepressant action: beyond NMDA receptor inhibition. Expert Opin Ther Targets 20:1389–1392.  https://doi.org/10.1080/14728222.2016.1238899CrossRefPubMedGoogle Scholar
  38. Hashimoto K (2016c) Letter to the Editor: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity. Psychol Med 46:2449–2451.  https://doi.org/10.1017/S0033291716000969CrossRefPubMedGoogle Scholar
  39. Hashimoto K (2017) Rapid antidepressant activity of ketamine beyond NMDA receptor. In: The NMDA receptors. Springer, Berlin, pp 69–81CrossRefGoogle Scholar
  40. Hashimoto K (2019) Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Psychiatry Clin Neurosci 73(10):613–627.  https://doi.org/10.1111/pcn.12902CrossRefPubMedPubMedCentralGoogle Scholar
  41. Hashimoto K, Kakiuchi T, Ohba H, Nishiyama S, Tsukada H (2017) Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci 267:173–176CrossRefGoogle Scholar
  42. Heal DJ, Gosden J, Smith SL (2018) Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans. Neuropharmacology 142:89–115.  https://doi.org/10.1016/j.neuropharm.2018.01.049CrossRefPubMedGoogle Scholar
  43. Hollis F, Kabbaj M (2014) Social defeat as an animal model for depression. ILAR J 55:221–232.  https://doi.org/10.1093/ilar/ilu002CrossRefPubMedGoogle Scholar
  44. Ide S, Ikekubo Y, Mishina M, Hashimoto K, Ikeda K (2017) Role of NMDA receptor GluN2D subunit in the antidepressant effects of enantiomers of ketamine. J Pharmacol Sci 135:138–140.  https://doi.org/10.1016/j.jphs.2017.11.001CrossRefPubMedPubMedCentralGoogle Scholar
  45. Imre G, Salomons A, Jongsma M, Fokkema DS, Den Boer JA, Ter Horst GJ (2006) Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat. Pharmacol Biochem Behav 84:392–399.  https://doi.org/10.1016/j.pbb.2006.05.021CrossRefPubMedGoogle Scholar
  46. Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan CJA (2018) Ketamine for the treatment of addiction: evidence and potential mechanisms. Neuropharmacology 142:72–82.  https://doi.org/10.1016/j.neuropharm.2018.01.017CrossRefPubMedGoogle Scholar
  47. Jarventausta K et al (2013) Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. J ECT 29:158–161.  https://doi.org/10.1097/YCT.0b013e318283b7e9CrossRefPubMedGoogle Scholar
  48. Jewett BE, Thapa B (2019) Physiology, NMDA Receptor. In: StatPearls. StatPearls, Treasure Island, FLGoogle Scholar
  49. Ji M et al (2019) Acute ketamine administration attenuates lipopolysaccharide-induced depressive-like behavior by reversing abnormal regional homogeneity in the nucleus accumbens. Neuroreport 30:421–427.  https://doi.org/10.1097/WNR.0000000000001219CrossRefPubMedGoogle Scholar
  50. Kallmunzer B, Volbers B, Karthaus A, Tektas OY, Kornhuber J, Muller HH (2016) Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression. J Neural Transm (Vienna) 123:549–552.  https://doi.org/10.1007/s00702-015-1500-7CrossRefGoogle Scholar
  51. Kharasch ED, Labroo R (1992) Metabolism of ketamine stereoisomers by human liver microsomes. Anesthesiology 77:1201–1207CrossRefGoogle Scholar
  52. Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, Correll CU (2016) Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med 46:1459–1472.  https://doi.org/10.1017/S0033291716000064CrossRefPubMedPubMedCentralGoogle Scholar
  53. Kohrs R, Durieux ME (1998) Ketamine: teaching an old drug new tricks. Anesth Analg 87:1186–1193Google Scholar
  54. Koike H, Iijima M, Chaki S (2011) Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224:107–111.  https://doi.org/10.1016/j.bbr.2011.05.035CrossRefPubMedGoogle Scholar
  55. Krishnan V, Nestler EJ (2011) Animal models of depression: molecular perspectives. Curr Top Behav Neurosci 7:121–147.  https://doi.org/10.1007/7854_2010_108CrossRefPubMedPubMedCentralGoogle Scholar
  56. Krystal JH et al (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214.  https://doi.org/10.1001/archpsyc.1994.03950030035004CrossRefPubMedPubMedCentralGoogle Scholar
  57. Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS (2019) Ketamine: a paradigm shift for depression research and treatment. Neuron 101:774–778.  https://doi.org/10.1016/j.neuron.2019.02.005CrossRefPubMedGoogle Scholar
  58. Kurdi MS, Theerth KA, Deva RS (2014) Ketamine: current applications in anesthesia, pain, and critical care. Anesth Essays Res 8:283–290.  https://doi.org/10.4103/0259-1162.143110CrossRefPubMedPubMedCentralGoogle Scholar
  59. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6:869–872CrossRefGoogle Scholar
  60. Lapidus KA et al (2014) A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 76:970–976.  https://doi.org/10.1016/j.biopsych.2014.03.026CrossRefPubMedPubMedCentralGoogle Scholar
  61. Li L, Vlisides PE (2016) Ketamine: 50 years of modulating the mind. Front Hum Neurosci 10:612.  https://doi.org/10.3389/fnhum.2016.00612CrossRefPubMedPubMedCentralGoogle Scholar
  62. Liao Y, Tang YI, Hao W (2017) Ketamine and international regulations. Am J Drug Alcohol Abuse 43:495–504CrossRefGoogle Scholar
  63. Liriano F, Hatten C, Schwartz TL (2019) Ketamine as treatment for post-traumatic stress disorder: a review. Drugs Context 8:212305.  https://doi.org/10.7573/dic.212305CrossRefPubMedPubMedCentralGoogle Scholar
  64. Luft A, Mendes FF (2005) Low S(+) ketamine doses: a review. Rev Bras Anestesiol 55:460–469CrossRefGoogle Scholar
  65. Ma J, Leung LS (2018) Involvement of posterior cingulate cortex in ketamine-induced psychosis relevant behaviors in rats. Behav Brain Res 338:17–27.  https://doi.org/10.1016/j.bbr.2017.09.051CrossRefPubMedGoogle Scholar
  66. Ma XC et al (2013) Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One 8:e56053.  https://doi.org/10.1371/journal.pone.0056053CrossRefPubMedPubMedCentralGoogle Scholar
  67. Marietta MP, Way WL, Castagnoli N Jr, Trevor AJ (1977) On the pharmacology of the ketamine enantiomorphs in the rat. J Pharmacol Exp Ther 202:157–165PubMedGoogle Scholar
  68. McCloud TL et al (2015) Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev:CD011611.  https://doi.org/10.1002/14651858.CD011611.pub2
  69. Molero P, Ramos-Quiroga J, Martin-Santos R, Calvo-Sánchez E, Gutiérrez-Rojas L, Meana JJ (2018) Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs 32:411–420CrossRefGoogle Scholar
  70. Morgan CJA, Curran HV (2012) Ketamine use: a review. Addiction 107:27–38.  https://doi.org/10.1111/j.1360-0443.2011.03576.xCrossRefPubMedPubMedCentralGoogle Scholar
  71. Muller J, Pentyala S, Dilger J, Pentyala S (2016) Ketamine enantiomers in the rapid and sustained antidepressant effects. Ther Adv Psychopharmacol 6:185–192.  https://doi.org/10.1177/2045125316631267CrossRefPubMedPubMedCentralGoogle Scholar
  72. Murrough JW et al (2013a) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:1134–1142.  https://doi.org/10.1176/appi.ajp.2013.13030392CrossRefPubMedPubMedCentralGoogle Scholar
  73. Murrough JW et al (2013b) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74:250–256.  https://doi.org/10.1016/j.biopsych.2012.06.022CrossRefPubMedGoogle Scholar
  74. Newport DJ et al (2015) Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 172:950–966.  https://doi.org/10.1176/appi.ajp.2015.15040465CrossRefPubMedGoogle Scholar
  75. Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N (2017) Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Curr Med Res Opin 33:701–711.  https://doi.org/10.1080/03007995.2016.1277201CrossRefPubMedGoogle Scholar
  76. Parsaik AK, Singh B, Khosh-Chashm D, Mascarenhas SS (2015) Efficacy of ketamine in bipolar depression: systematic review and meta-analysis. J Psychiatr Pract 21:427–435.  https://doi.org/10.1097/PRA.0000000000000106CrossRefGoogle Scholar
  77. Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M (2010) Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry 43:33–35.  https://doi.org/10.1055/s-0029-1237375CrossRefPubMedGoogle Scholar
  78. Paul R, Schaaff N, Padberg F, Moller HJ, Frodl T (2009) Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry 10:241–244.  https://doi.org/10.1080/15622970701714370CrossRefPubMedGoogle Scholar
  79. Phillips JL et al (2019) Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry 176:401–409.  https://doi.org/10.1176/appi.ajp.2018.18070834CrossRefPubMedGoogle Scholar
  80. Pittenger C, Sanacora G, Krystal JH (2007) The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets 6:101–115CrossRefGoogle Scholar
  81. Qu Y, Yang C, Ren Q, Ma M, Dong C, Hashimoto K (2017) Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model. Sci Rep 7:15725.  https://doi.org/10.1038/s41598-017-16060-7CrossRefPubMedPubMedCentralGoogle Scholar
  82. Read J, Cunliffe S, Jauhar S, McLoughlin DM (2019) Should we stop using electroconvulsive therapy? BMJ 364:k5233.  https://doi.org/10.1136/bmj.k5233CrossRefPubMedGoogle Scholar
  83. Reinstatler L, Youssef NA (2015) Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature. Drugs R D 15:37–43.  https://doi.org/10.1007/s40268-015-0081-0CrossRefPubMedPubMedCentralGoogle Scholar
  84. Remus JL, Dantzer R (2016) Inflammation models of depression in rodents: relevance to psychotropic drug discovery. Int J Neuropsychopharmacol 19:pyw028.  https://doi.org/10.1093/ijnp/pyw028CrossRefPubMedPubMedCentralGoogle Scholar
  85. Reus GZ et al (2015) A single dose of S-ketamine induces long-term antidepressant effects and decreases oxidative stress in adulthood rats following maternal deprivation. Dev Neurobiol 75:1268–1281.  https://doi.org/10.1002/dneu.22283CrossRefPubMedPubMedCentralGoogle Scholar
  86. Reus GZ et al (2017) Ketamine potentiates oxidative stress and influences behavior and inflammation in response to lipolysaccharide (LPS) exposure in early life. Neuroscience 353:17–25.  https://doi.org/10.1016/j.neuroscience.2017.04.016CrossRefPubMedGoogle Scholar
  87. Rosenblat JD, Carvalho AF, Li M, Lee Y, Subramanieapillai M, McIntyre RS (2019) Oral ketamine for depression: a systematic review. J Clin Psychiatry 80.  https://doi.org/10.4088/JCP.18r12475
  88. Sanacora G et al (2017) A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiat 74:399–405.  https://doi.org/10.1001/jamapsychiatry.2017.0080CrossRefGoogle Scholar
  89. Schwartz J, Murrough JW, Iosifescu DV (2016) Ketamine for treatment-resistant depression: recent developments and clinical applications. Evid Based Ment Health 19:35–38.  https://doi.org/10.1136/eb-2016-102355CrossRefPubMedGoogle Scholar
  90. Segmiller F et al (2013) Repeated S-ketamine infusions in therapy resistant depression: a case series. J Clin Pharmacol 53:996–998.  https://doi.org/10.1002/jcph.122CrossRefPubMedGoogle Scholar
  91. Serafini G, Howland RH, Rovedi F, Girardi P, Amore M (2014) The role of ketamine in treatment-resistant depression: a systematic review. Curr Neuropharmacol 12:444–461.  https://doi.org/10.2174/1570159x12666140619204251CrossRefPubMedPubMedCentralGoogle Scholar
  92. Sheth MK, Brand A, Halterman J (2018) Ketamine-induced changes in blood pressure and heart rate in pre-hospital intubated patients. Adv J Grad Res 3:20–33CrossRefGoogle Scholar
  93. Shirayama Y, Hashimoto K (2017) Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. Eur Arch Psychiatry Clin Neurosci 267:177–182.  https://doi.org/10.1007/s00406-016-0718-1CrossRefPubMedGoogle Scholar
  94. Short B, Fong J, Galvez V, Shelker W, Loo CK (2018) Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry 5:65–78.  https://doi.org/10.1016/S2215-0366(17)30272-9CrossRefPubMedGoogle Scholar
  95. Sihra N, Ockrim J, Wood D (2018) The effects of recreational ketamine cystitis on urinary tract reconstruction—a surgical challenge. BJU Int 121:458–465.  https://doi.org/10.1111/bju.14094CrossRefPubMedPubMedCentralGoogle Scholar
  96. Singh JB et al (2016) Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 80:424–431.  https://doi.org/10.1016/j.biopsych.2015.10.018CrossRefGoogle Scholar
  97. Singh I, Morgan C, Curran V, Nutt D, Schlag A, McShane R (2017) Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. Lancet Psychiatry 4:419–426.  https://doi.org/10.1016/S2215-0366(17)30102-5CrossRefPubMedGoogle Scholar
  98. Sinner B, Graf BM (2008) Ketamine. Handb Exp Pharmacol:313–333.  https://doi.org/10.1007/978-3-540-74806-9_15
  99. Soumier A, Carter RM, Schoenfeld TJ, Cameron HA (2016) New hippocampal neurons mature rapidly in response to ketamine but are not required for its acute antidepressant effects on neophagia in rats. eNeuro 3.  https://doi.org/10.1523/ENEURO.0116-15.2016CrossRefGoogle Scholar
  100. Stevenson C (2005) Ketamine: a review. Update Anaesth 20:25–29Google Scholar
  101. Strong CE, Kabbaj M (2018) On the safety of repeated ketamine infusions for the treatment of depression: effects of sex and developmental periods. Neurobiol Stress 9:166–175.  https://doi.org/10.1016/j.ynstr.2018.09.001CrossRefPubMedPubMedCentralGoogle Scholar
  102. Sun HL et al (2016) Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model. Transl Psychiatry 6:e741.  https://doi.org/10.1038/tp.2016.21CrossRefPubMedPubMedCentralGoogle Scholar
  103. Szlachta M et al (2017) Effect of clozapine on ketamine-induced deficits in attentional set shift task in mice. Psychopharmacology (Berl) 234:2103–2112.  https://doi.org/10.1007/s00213-017-4613-xCrossRefGoogle Scholar
  104. Thomson AM, West DC, Lodge D (1985) An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? Nature 313:479–481CrossRefGoogle Scholar
  105. Tian Z, Dong C, Fujita A, Fujita Y, Hashimoto K (2018a) Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine. Pharmacol Biochem Behav 172:17–21.  https://doi.org/10.1016/j.pbb.2018.07.003CrossRefPubMedGoogle Scholar
  106. Tian Z, Dong C, Zhang K, Chang L, Hashimoto K (2018b) Lack of antidepressant effects of low-voltage-sensitive T-type calcium channel blocker ethosuximide in a chronic social defeat stress model: comparison with (R)-ketamine. Int J Neuropsychopharmacol 21:1031–1036.  https://doi.org/10.1093/ijnp/pyy072CrossRefPubMedPubMedCentralGoogle Scholar
  107. Tracy DK, Wood DM, Baumeister D (2017) Novel psychoactive substances: types, mechanisms of action, and effects. BMJ 356:i6848.  https://doi.org/10.1136/bmj.i6848CrossRefPubMedGoogle Scholar
  108. Treccani G et al (2019) S-ketamine reverses hippocampal dendritic spine deficits in flinders sensitive line rats within 1 h of administration. Mol Neurobiol 56(11):7368–7379.  https://doi.org/10.1007/s12035-019-1613-3CrossRefPubMedGoogle Scholar
  109. Trimmel H, Helbok R, Staudinger T, Jaksch W, Messerer B, Schochl H, Likar R (2018) S(+)-ketamine: Current trends in emergency and intensive care medicine. Wien Klin Wochenschr 130:356–366.  https://doi.org/10.1007/s00508-017-1299-3CrossRefPubMedPubMedCentralGoogle Scholar
  110. US Food and Drug Administration (2019) FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. PressAnnouncements/ucm632761.htmGoogle Scholar
  111. Veraart JKE, Smith-Apeldoorn SY, Trueman H, de Boer MK, Schoevers RA, McShane R (2018) Characteristics of patients expressing an interest in ketamine treatment: results of an online survey. BJPsych Open 4:389–392.  https://doi.org/10.1192/bjo.2018.51CrossRefPubMedPubMedCentralGoogle Scholar
  112. Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J (1997) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7:25–38CrossRefGoogle Scholar
  113. White PF, Schuttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ (1985) Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth 57:197–203.  https://doi.org/10.1093/bja/57.2.197CrossRefPubMedGoogle Scholar
  114. Wilkinson ST et al (2018) The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry 175:150–158.  https://doi.org/10.1176/appi.ajp.2017.17040472CrossRefGoogle Scholar
  115. World Health Organization (2011) WHO model list of essential medicines: 17th list, March 2011Google Scholar
  116. World Health Organization (2017) Depression and other common mental disorders: global health estimates (No. WHO/MSD/MER/2017.2). World Health OrganizationGoogle Scholar
  117. Xiong Z, Zhang K, Ishima T, Ren Q, Chang L, Chen J, Hashimoto K (2018) Comparison of rapid and long-lasting antidepressant effects of negative modulators of alpha5-containing GABAA receptors and (R)-ketamine in a chronic social defeat stress model. Pharmacol Biochem Behav 175:139–145.  https://doi.org/10.1016/j.pbb.2018.10.005CrossRefPubMedGoogle Scholar
  118. Xiong Z et al (2019) Lack of rapid antidepressant effects of Kir4.1 channel inhibitors in a chronic social defeat stress model: Comparison with (R)-ketamine. Pharmacol Biochem Behav 176:57–62.  https://doi.org/10.1016/j.pbb.2018.11.010CrossRefPubMedGoogle Scholar
  119. Yang C et al (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632.  https://doi.org/10.1038/tp.2015.136CrossRefPubMedPubMedCentralGoogle Scholar
  120. Yang B et al (2016a) Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl) 233:3647–3657.  https://doi.org/10.1007/s00213-016-4399-2CrossRefGoogle Scholar
  121. Yang C, Han M, Zhang JC, Ren Q, Hashimoto K (2016b) Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res 239:281–283.  https://doi.org/10.1016/j.psychres.2016.03.034CrossRefGoogle Scholar
  122. Yang C, Qu Y, Fujita Y, Ren Q, Ma M, Dong C, Hashimoto K (2017) Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model. Transl Psychiatry 7:1294.  https://doi.org/10.1038/s41398-017-0031-4CrossRefPubMedPubMedCentralGoogle Scholar
  123. Yang C, Ren Q, Qu Y, Zhang JC, Ma M, Dong C, Hashimoto K (2018a) Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry 83:18–28.  https://doi.org/10.1016/j.biopsych.2017.05.016CrossRefPubMedPubMedCentralGoogle Scholar
  124. Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, Hu H (2018b) Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature 554:317–322.  https://doi.org/10.1038/nature25509CrossRefGoogle Scholar
  125. Zanos P, Gould TD (2018) Intracellular signaling pathways involved in (s)- and (r)-ketamine antidepressant actions. Biol Psychiatry 83:2–4.  https://doi.org/10.1016/j.biopsych.2017.10.026CrossRefPubMedPubMedCentralGoogle Scholar
  126. Zanos P, Nelson ME, Highland JN, Krimmel SR, Georgiou P, Gould TD, Thompson SM (2017) A negative allosteric modulator for alpha5 subunit-containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA receptor antagonist ketamine in mice. eNeuro 4.  https://doi.org/10.1523/ENEURO.0285-16.2017CrossRefGoogle Scholar
  127. Zanos P et al (2018) Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 70:621–660.  https://doi.org/10.1124/pr.117.015198CrossRefPubMedPubMedCentralGoogle Scholar
  128. Zarate CA Jr et al (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864.  https://doi.org/10.1001/archpsyc.63.8.856CrossRefPubMedPubMedCentralGoogle Scholar
  129. Zeilhofer HU, Swandulla D, Geisslinger G, Brune K (1992) Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur J Pharmacol 213:155–158CrossRefGoogle Scholar
  130. Zhan Y et al (2019) A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. J Affect Disord 251:205–212.  https://doi.org/10.1016/j.jad.2019.03.071CrossRefPubMedGoogle Scholar
  131. Zhang K, Hashimoto K (2019) An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Rev Neurother 19:83–92.  https://doi.org/10.1080/14737175.2019.1554434CrossRefPubMedGoogle Scholar
  132. Zhang JC, Li SX, Hashimoto K (2014) R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 116:137–141.  https://doi.org/10.1016/j.pbb.2013.11.033CrossRefPubMedPubMedCentralGoogle Scholar
  133. Zhang JC et al (2015) Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl) 232:4325–4335.  https://doi.org/10.1007/s00213-015-4062-3CrossRefGoogle Scholar
  134. Zhang GF et al (2016) Acute single dose of ketamine relieves mechanical allodynia and consequent depression-like behaviors in a rat model. Neurosci Lett 631:7–12.  https://doi.org/10.1016/j.neulet.2016.08.006CrossRefGoogle Scholar
  135. Zhang K, Dong C, Fujita Y, Fujita A, Hashimoto K (2018) 5-hydroxytryptamine-independent antidepressant actions of (R)-ketamine in a chronic social defeat stress model. Int J Neuropsychopharmacol 21:157–163.  https://doi.org/10.1093/ijnp/pyx100CrossRefPubMedPubMedCentralGoogle Scholar
  136. Zhao J, Wang Y, Wang D (2018) The effect of ketamine infusion in the treatment of complex regional pain syndrome: a systemic review and meta-analysis. Curr Pain Headache Rep 22:12.  https://doi.org/10.1007/s11916-018-0664-xCrossRefPubMedGoogle Scholar
  137. Zheng W et al (2018) Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. J Psychiatr Res 106:61–68.  https://doi.org/10.1016/j.jpsychires.2018.09.013CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Division of Clinical NeuroscienceChiba University Center for Forensic Mental HealthChibaJapan
  2. 2.Key Laboratory of Medical Electrophysiology of Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Collaborative Innovation Center for Prevention and Treatment of Cadiovascular Disease, Institute of Cardiovascular ResearchSouthwest Medical UniversityLuzhouChina

Personalised recommendations